Dr
Michael
Holmes

Patent Director

Manchester Office

Chemistry

Telephone. +44(0) 161 247 4900
Mobile. +44(0) 787 911 5005
Email. [email protected]

Experience

Mike is a talented and experienced Patent Attorney (chemistry and pharmaceutical specialist), whose sharp strategic focus and passion for business lends a generous commercial edge to the legal services he offers. He has drafted and prosecuted numerous patent applications, and has managed many significant global patent portfolios on behalf of some of the world’s major industrial giants.

Mike frequently delivers legal opinions (e.g. freedom-to-operate, due diligence, and patentability) alongside cogent strategic advice to facilitate clients’ decision making at board and technical/operational levels. He often works closely with HGF’s IP solicitors, both in litigation and contractual matters, as part of a full service IP team. Mike's work on pan-European litigation teams has also delivered huge rewards for his blue-chip clients.

Qualifications

Patent Attorney

Chartered (UK)
European

Trade Mark Attorney

Chartered (UK)
European


MCHEM

1st Class MChem (Oxon) in Chemistry

PHD

PhD (Manc) in Chemistry

Related News

Artificial intelligence inventions in healthcare – can you patent them in Europe?

Artificial Intelligence (AI) has moved from the realm of science fiction firmly into the mainstream of technological innovation. Trained AI models in some cases are able to perform data analysis …

Read article

3D shape trade marks for medical devices

Innovation in medical devices continues strongly and the introduction of IoT and 3D printing (amongst others) has led to an acceleration in new medical devices. Whilst patents and designs are …

Read article

Patenting digital mental health

Mental health and behavioural disorders have a profound impact on wellbeing worldwide, with an estimated 13% of the global population suffering from a mental health or substance use disorder [1]. …

Read article

“For medical purposes” – a case for unblurring the lines between pharma and nutritional products

Food-pharma industry convergence is not a new development. In 2013, a study of the patent citation data of 274 published European patents by 5 EU Medical Nutrition companies revealed the …

Read article

Patenting antibodies in the US and Europe

Is the USPTO now stricter than the EPO on antibody claims? A consideration of recent developments from both sides of the pond. Patent protection for monoclonal antibodies, bispecific antibodies and …

Read article

Patentability of Simulations in Europe

Simulations offer a powerful tool in modern-day engineering. Subjecting designs to initial testing in a simulated environment will, for many designs, reduce costs owing to reduced needs to produce and …

Read article
Event - 30th April 2022

INTA 2022 Annual Meeting Live+

The HGF European team will be attending the INTA 2022 Annual Meeting Live+. It is being held on 30th April – 4th May in Washington, D.C. INTA brings together the …

Event details

Blockbuster blood thinning patent revoked

Summary Mr Justice Meade has revoked Bristol Myers Squibb’s (BMS) European patent No. EP1427415 (EP’415) and corresponding supplementary protection certificate (SPC) that relate to the compound Apixaban (ELIQUIS) for lack …

Read article

Let's talk

If you would like to discuss how HGF could help you, contact one of our IP specialists.